The main purpose of this legislative text is to make the process for reviewing biosimilar biological products more efficient. Biosimilars are medications that are highly similar to already approved biological products, and streamlining their review can help bring these potentially lower-cost alternatives to market more quickly. Key provisions of this legislation focus on amending a specific part of the Public Health Service Act. It proposes to remove a certain requirement that is currently part of the review process for biosimilars.